$QURE

uniQure N.V.

uniQure is a gene therapy company developing treatments for rare and other serious diseases. Its clinical-stage candidates include AMT-130 for Huntington’s disease, AMT-260 for refractory mesial temporal lobe epilepsy, AMT-191 for Fabry disease and AMT-162 for SOD1-ALS. The company also develops early-stage gene therapy programs and technologies for delivery and therapeutic cargo, including its miQURE gene-silencing platform. It conducts clinical studies of its candidates and aims to advance them toward potential commercialization. uniQure earns royalties through an agreement granting CSL Behring exclusive global rights to HEMGENIX for hemophilia B, and supplies the product for CSL Behring’s commercial demand through Genezen. Its business also includes developing AAV-based gene therapies using owned and licensed technologies. The company is headquartered in Amsterdam.

1
1
1
—
$193K
Meek David D.
100%
See all $QURE insider activity →

QURE Stock Rallies 17.5% in a Month: What Should Investors Do Now?

uniQure N.V. (QURE) shares rose 17.5% in a month, outperforming the industry and S&P 500. The rally was driven by FDA acceptance of its Huntington's disease drug application, ifezuntirgene inilparvovec, for review. Despite weaker Q3 2026 results, investors focus on the drug's potential. QURE's cash position is strong, with $768.4M as of Sept. 30, 2026, expected to fund operations through 2030.

QURE sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 3 news stories mentioning QURE (uniQure N.V.). Coverage has been balanced: 1 bullish, 1 neutral, and 1 bearish.

Recent QURE coverage spans regulation, financial news and earnings.

In the last 30 days, QURE insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($193K). The most active reporter was Meek David D. with 1 filing. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.

What's driving QURE

  • Analyst valuation reset likely pressures near-term sentiment, even with the Buy rating unchanged.

    tradingview.com · Nov 18, 2026

  • uniQure CEO Matt Kapusta defended AMT-130's four-year data, citing high-dose patients' average annual loss of less than 0.1 Total Functional Capacity points. The FDA will review the application using the original dataset. uniQure plans a 200-patient confirmatory study, aiming to show progress before the FDA decision.

    finance.yahoo.com · Nov 13, 2026

  • The regulatory milestone is likely to lift the stock as investors price in a potential approval and commercial launch.

    tradingview.com · Nov 13, 2026

  • The upcoming FDA panel could determine approval, creating significant upside if positive and downside risk if negative.

    finance.yahoo.com · Nov 13, 2026

  • Acceptance of the marketing application and a defined decision date improves visibility for a key regulatory milestone.

    mmm-online.com · Nov 6, 2026

AlphAI scores every news story that mentions QURE with an AI model for sentiment and relevance, and aggregates insider trades from uniQure N.V.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $QURE

Score

QURE Stock Rallies 17.5% in a Month: What Should Investors Do Now?

uniQure N.V. (QURE) shares rose 17.5% in a month, outperforming the industry and S&P 500. The rally was driven by FDA acceptance of its Huntington's disease drug application, ifezuntirgene inilparvovec, for review. Despite weaker Q3 2026 results, investors focus on the drug's potential. QURE's cash position is strong, with $768.4M as of Sept. 30, 2026, expected to fund operations through 2030.

uniQure Prepares for Potential FDA Panel on Huntington’s Gene Therapy After Priority Review Nod

uniQure (QURE) is preparing for a potential FDA panel review of its gene therapy AMT-130 for Huntington's disease after receiving a priority review nod. The company presented 48-month data showing treated patients had less functional decline than untreated ones, though control group limitations were noted. uniQure plans a confirmatory study and is preparing for a potential launch, with $780 million in cash to fund operations into 2030.

Rx Rundown: Boehringer Ingelheim, Teva, 120/80 Health Group and more

AstraZeneca offered $10B for Rhythm Pharmaceuticals. Boehringer Ingelheim licensed 6 cancer drugs from Sino Biopharmaceutical for $358M upfront. AbbVie licensed Nxera Pharma’s program for $100M. Lonza acquired 5 CDMO sites from Merck KGaA. Teva and Samsung Bioepis licensed 2 biosimilars. FDA approved Inovio’s Voceryq, sending shares up 257%. Agios, UniQure, NRx Pharma had FDA updates. Formation Bio raised $600M. Molecular Partners, Lenz Therapeutics, Ultragenyx announced layoffs.

$QUREHighAI 8/10Earnings

uniQure Announces Third Quarter 2026 Financial Results and Provides Company Update

uniQure N.V. (QURE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 uniQure Announces Third Quarter 2026 Financial Results and Provides Company Update ~ FDA granted priority review of BLA for ifezuntirgene inilparvovec (AMT-130) in Huntington’s disease; PDUFA target action date of May 1, 2027 ~ ~ Aligned with FDA on key elements of c

Related tickers